Belantamab Mafodotin

Names

[ CAS No. ]:
2050232-20-5

[ Name ]:
Belantamab Mafodotin

Biological Activity

[Description]:

Belantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2].

[Related Catalog]:

Research Areas >> Cancer

[In Vitro]

Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2]. Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2]. Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2].

[In Vivo]

Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. Animal Model: Mice harbouring OPM2 tumours[2] Dosage: 4 mg/kg Administration: IP, twice weekly for 4 doses Result: Signifcantly improves survival compared to vehicle.

[References]

[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.

[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.